A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

Peng, Jinfang; Fan, Mingjie; An, Chelsea; Ni, Feng; Huang, Wendong; Luo, Jiankang

doi:10.1111/bcpt.13710

Cited by 140 publications

(144 citation statements)

References 163 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Cannabidiol is a non-psychoactive component abundant in Cannabis sativa L. (marijuana), which preliminarily studied has shown to have a protective role aganist hepatic steatosis ( Peng et al, 2022 ). The administration of cannabidiol may help to ameliorate symptoms of NAFLD induced by HFD and can significantly inhibit the nuclear translocation of NF-κBp65 and NLRP3 inflammasome activation, helping to reduce the expression of inflammatory factors in vivo and in vitro .…”

Section: Pharmacological Agents Associated With Nlrp3 Inflammasome Su...mentioning

confidence: 99%

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent primary liver diseases worldwide and can develop into various conditions, ranging from simple steatosis, through non-alcoholic steatohepatitis (NASH), to fibrosis, and eventually cirrhosis and hepatocellular carcinoma. Nevertheless, there is no effective treatment for NAFLD due to the complicated etiology. Recently, activation of the NLPR3 inflammasome has been demonstrated to be a contributing factor in the development of NAFLD, particularly as a modulator of progression from initial hepatic steatosis to NASH. NLRP3 inflammasome, as a caspase-1 activation platform, is critical for processing key pro-inflammatory cytokines and pyroptosis. Various stimuli involved in NAFLD can activate the NLRP3 inflammasome, depending on the diverse cellular stresses that they cause. NLRP3 inflammasome-related inhibitors and agents for NAFLD treatment have been tested and demonstrated positive effects in experimental models. Meanwhile, some drugs have been applied in clinical studies, supporting this therapeutic approach. In this review, we discuss the activation, biological functions, and treatment targeting the NLRP3 inflammasome in the context of NAFLD progression. Specifically, we focus on the different types of therapeutic agents that can inhibit the NLRP3 inflammasome and summarize their pharmacological effectiveness for NAFLD treatment.

show abstract

Section: Pharmacological Agents Associated With Nlrp3 Inflammasome Su...mentioning

confidence: 99%

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Moreover, the effects of CBD prolonging increases in locomotion induced by ketamine, associated with potential antischizophrenic properties, suggest its possible influence on glutamatergic system involvement in motivation and motor activity [ 78 ]. CBD has a high affinity for the GPR55 receptor [ 84 ], and expression of this receptor was found to be profoundly downregulated in the striatum of rodents in experimental PD models, raising the hypothesis that GPR55 might be involved in the development of this pathology and that CBD could be a potential therapeutic tool for PD [ 85 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Cannabidiol on Locomotor Activity

Calapai

Cardia

Calapai

et al. 2022

Life

View full text Add to dashboard Cite

Cannabidiol (CBD) is the second cannabinoid, in order of importance after Δ9-tetrahydrocannabinol (THC), from Cannabis sativa. Unlike THC, CBD does not cause psychotomimetic effects, and although these compounds have the same chemical formula, their pharmacological characteristics are not equivalent. Preclinical studies suggest that CBD has anti-inflammatory, analgesic, anxiolytic, antiemetic, anticonvulsant, and antipsychotic properties and influences the sleep–wake cycle. The evaluation of effects on spontaneous motor activity is crucial in experimental pharmacology, and the careful measurement of laboratory animal movement is an established method to recognize the effects of stimulant and depressant drugs. The potential influence of CBD on locomotor activity has been investigated through numerous in vivo experiments. However, there is no clear picture of the impact of CBD on these issues, even though it is administered alone for medical uses and sold with THC as a drug for pain caused by muscle spasms in multiple sclerosis, and it was recently licensed as a drug for severe forms of infantile epilepsy. On this basis, with the aim of developing deeper knowledge of this issue, scientific data on CBD’s influence on locomotor activity are discussed here. We conducted research using PubMed, Scopus, Google Scholar, and a search engine for literature between January 2009 and December 2021 on life sciences and biomedical topics using the keywords “motor activity”, “locomotor activity”, and “locomotion” in combination with “cannabidiol”. In this article, we discuss findings describing the effects on locomotor activity of the CBD precursor cannabidiolic acid and of CBD alone or in combination with THC, together with the effects of CBD on locomotor modifications induced by diseases and on locomotor changes induced by other substances.

show abstract

“…CBD acts as an antagonist for CB1 and CB2 cannabinoid receptors (Pertwee et al., 2002 ; Thomas et al., 2007 ; Peng et al., 2022 ). CB1 receptors are mainly distributed in the central nervous system, and they are particularly abundant in brain areas associated with motor control, emotional responses, motivated behaviour and energy homoeostasis (Freund et al., 2003 ; Cristino et al., 2020 ).…”

Section: Limitations and Uncertainties In Scientific Literaturementioning

confidence: 99%

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties

Turck¹,

Bohn²,

Castenmiller³

et al. 2022

EFS2

View full text Add to dashboard Cite

The European Commission has determined that cannabidiol (CBD) can be considered as a novel food (NF), and currently, 19 applications are under assessment at EFSA. While assessing these, it has become clear that there are knowledge gaps that need to be addressed before a conclusion on the safety of CBD can be reached. Consequently, EFSA has issued this statement, summarising the state of knowledge on the safety of CBD consumption and highlighting areas where more data are needed. Literature searches for both animal and human studies have been conducted to identify safety concerns. Many human studies have been carried out with Epidyolex ® , a CBD drug authorised to treat refractory epilepsies. In the context of medical conditions, adverse effects are tolerated if the benefit outweighs the adverse effect. This is, however, not acceptable when considering CBD as a NF. Furthermore, most of the human data referred to in the CBD applications investigated the efficacy of Epidyolex (or CBD) at therapeutic doses. No NOAEL could be identified from these studies. Given the complexity and importance of CBD receptors and pathways, interactions need to be taken into account when considering CBD as a NF. The effects on drug metabolism need to be clarified. Toxicokinetics in different matrices, the half‐life and accumulation need to be examined. The effect of CBD on liver, gastrointestinal tract, endocrine system, nervous system and on psychological function needs to be clarified. Studies in animals show significant reproductive toxicity, and the extent to which this occurs in humans generally and in women of child‐bearing age specifically needs to be assessed. Considering the significant uncertainties and data gaps, the Panel concludes that the safety of CBD as a NF cannot currently be established.

show abstract

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

Cited by 140 publications

References 163 publications

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

Effects of Cannabidiol on Locomotor Activity

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties

Contact Info

Product

Resources

About